Linezolid: an oxazolidinone antimicrobial agent

Area of Science:

• Pharmacology and Infectious Diseases
• Antimicrobial Resistance
• Drug Development

Background:

• Linezolid is the sole oxazolidinone antimicrobial approved in the U.S.
• It exhibits potent activity against challenging gram-positive pathogens, including vancomycin-resistant strains.
• The drug's unique mechanism inhibits bacterial protein synthesis, preventing translation.

Purpose of the Study:

• To review the pharmacology, antimicrobial activity, pharmacokinetics, clinical efficacy, and adverse effects of linezolid.
• To assess linezolid's role in treating infections caused by resistant gram-positive bacteria.
• To evaluate linezolid as a therapeutic alternative for specific patient populations.

Main Methods:

• Review of existing pharmacological and clinical data.
• Analysis of antimicrobial activity against resistant gram-positive bacteria.
• Evaluation of pharmacokinetic properties, including oral bioavailability and half-life.
• Assessment of clinical trial data for efficacy and safety.

Main Results:

• Linezolid demonstrates significant activity against gram-positive bacteria, including vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus (MRSA).
• It has a favorable pharmacokinetic profile, allowing twice-daily dosing and 1:1 IV-to-oral conversion.
• Clinical trials confirm efficacy in pneumonia and skin infections; adverse effects are generally mild, with reversible myelosuppression noted in some cases.

Conclusions:

• Linezolid is an effective and well-tolerated option for treating serious gram-positive infections, particularly those caused by resistant organisms.
• It offers a valuable therapeutic alternative for patients who cannot tolerate vancomycin.
• The drug's pharmacokinetic properties support convenient administration regimens.